The purpose of the study is to find out if high dose antibiotic (meropenem, MERREM® I.V.), along with another drug called an aminoglycoside (a different type of antibiotic) is effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa, Acinetobacter (germs that can cause pneumonia), and the rate of resistance in other difficult to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory support. The study hopes to show that by increasing the amount of meropenem administered and increasing the duration of infusion (release of the drug into the bloodstream), levels of the drug will stay at target levels in the bloodstream and decrease the ability of difficult to treat germs to resist, or not be killed by, the treatment using this antibiotic (meropenem) or other antibiotics.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
500
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Newark, Delaware, United States
Unnamed facility
Indianapolis, Indiana, United States
Unnamed facility
Boston, Massachusetts, United States
Unnamed facility
Lebanon, New Hampshire, United States
Unnamed facility
Albany, New York, United States
Unnamed facility
New York, New York, United States
Unnamed facility
Stony Brook, New York, United States
Unnamed facility
Cincinnati, Ohio, United States
Unnamed facility
San Antonio, Texas, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.